SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Author： Wong R.   Baetz T.   Krahn M.   Biagi J.   Wainman N.   Eisenhauer E.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.4, 2006-07, pp. : 347-351

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea: A phase II trial of the national cancer institute of canada clinical trials group

By Webster Marc   Cairncross Gregory   Gertler Stan   Perry James   Wainman Nancy   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 591-596

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

By Winquist Eric   Knox Jennifer   Ayoub Jean-Pierre   Wood Lori   Wainman Nancy   Reid Gregory   Pearce Laura   Shah Ajit   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 159-167

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

By Knowling M.   Blackstein M.   Tozer R.   Bramwell V.   Dancey J.   Dore N.   Matthews S.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 435-439

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

By Goss G.   Hirte H.   Miller W.   Lorimer I.   Stewart D.   Batist G.   Parolin D.   Hanna P.   Stafford S.   Friedmann J.   Walsh W.   Mathews S.   Douglas L.   Seymour L.  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 147-155

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

By Gelmon Karen   Belanger Karl   Soulieres Denis   Britten Carolyn   Chia Stephen   Charpentier Danielle   Chi Kim   Powers Jean   Walsh Wendy   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 445-453

Springer Publishing Company

Access to resources Recommend Favorite